Currently in AD, cholinesterase inhibitors and NMDA receptor antagonists offer brief cognitive symptomatic improvement [7], while newer therapies targeting Aβ, including lecanemab and donanemab, report modest disease-modifying effects, but long-term outcomes and safety remain unknown [8]. Here, BCHE is linked to Alzheimer disease.